Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy
With the recent regulatory approval of Talimogene laherparepvec (T-VEC) for the treatment of advanced of melanoma in the United States, Europe and Australia, oncolytic virus immunotherapy has earned its place in the clinic. However, the adoption of T-VEC by the U.S. oncology community has been slow,...
Na minha lista:
| Principais autores: | , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BMJ Publishing Group
2016-09-01
|
| coleção: | Journal for ImmunoTherapy of Cancer |
| Acesso em linha: | https://jitc.bmj.com/content/4/1/53.full |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|